Irinotecan regulatory update

FDA granted Fast Track designation to MM-398 to treat metastatic pancreatic cancer in patients who have been previously treated with gemcitabine-based therapy. Merrimack plans to begin a rolling NDA submission by year end and complete it in late 1Q15 or early 2Q15. ...